(CHE) Chemed - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US16359R1032
CHE EPS (Earnings per Share)
CHE Revenue
CHE: Hospice Care, Plumbing Services, Drain Cleaning, Water Restoration
Chemed Corporation is a multifaceted healthcare services provider and plumbing specialist, operating primarily in the United States through its VITAS and Roto-Rooter segments. The VITAS segment delivers hospice and palliative care services, leveraging a network of healthcare professionals to provide direct medical services, spiritual support, and emotional counseling to patients and their families. In contrast, the Roto-Rooter segment focuses on plumbing, drain cleaning, and related services for residential and commercial clients, utilizing a mix of company-owned branches, independent contractors, and franchisees. This diversified business model allows Chemed Corporation to maintain a strong presence in both the healthcare and plumbing services markets.
From a business perspective, Chemed Corporations operations are characterized by a high degree of specialization and a commitment to delivering high-quality services. The companys hospice and palliative care services are designed to provide comfort and support to patients with serious illnesses, while its plumbing services aim to address a range of customer needs, from routine maintenance to emergency repairs. By maintaining a strong network of professionals and a robust service infrastructure, Chemed Corporation is well-positioned to capitalize on growth opportunities in both its core markets.
Analyzing the available
In conclusion, Chemed Corporations diversified business model, strong financial profile, and growth prospects make it an attractive investment opportunity for investors seeking exposure to the healthcare services and plumbing industries. By closely monitoring the companys financial performance and market trends, investors can make informed decisions about their investment in Chemed Corporation.
Additional Sources for CHE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
CHE Stock Overview
Market Cap in USD | 8,315m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1973-05-03 |
CHE Stock Ratings
Growth Rating | 36.7 |
Fundamental | 79.3 |
Dividend Rating | 53.5 |
Rel. Strength | 9.96 |
Analysts | 4.67 of 5 |
Fair Price Momentum | 489.37 USD |
Fair Price DCF | 461.99 USD |
CHE Dividends
Dividend Yield 12m | 0.36% |
Yield on Cost 5y | 0.45% |
Annual Growth 5y | 6.40% |
Payout Consistency | 97.0% |
Payout Ratio | 8.5% |
CHE Growth Ratios
Growth Correlation 3m | -80% |
Growth Correlation 12m | 20.9% |
Growth Correlation 5y | 78.5% |
CAGR 5y | 4.12% |
CAGR/Max DD 5y | 0.16 |
Sharpe Ratio 12m | 0.95 |
Alpha | -2.98 |
Beta | 0.174 |
Volatility | 21.38% |
Current Volume | 165.1k |
Average Volume 20d | 109.5k |
As of June 18, 2025, the stock is trading at USD 549.65 with a total of 165,108 shares traded.
Over the past week, the price has changed by -0.76%, over one month by -4.83%, over three months by -9.53% and over the past year by +2.33%.
Yes, based on ValueRay´s Fundamental Analyses, Chemed (NYSE:CHE) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 79.26 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CHE is around 489.37 USD . This means that CHE is currently overvalued and has a potential downside of -10.97%.
Chemed has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy CHE.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, CHE Chemed will be worth about 530.7 in June 2026. The stock is currently trading at 549.65. This means that the stock has a potential downside of -3.44%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 677.3 | 23.2% |
Analysts Target Price | 677.3 | 23.2% |
ValueRay Target Price | 530.7 | -3.4% |